| Type | Public |
| HQ | Alpharetta, US |
| Founded | 2003 |
| Size (employees) | 118 (est)-5% |
| Website | alimerasciences.com |
Alimera Sciences was founded in 2003 and is headquartered in Alpharetta, US
Report incorrect company information
Viewing summary data as a guest
Sign up for free to see all dataKey People/Management at Alimera Sciences
Ken Greene
CSO
Susan Caballa
Sr. Vice President, Regulatory & Medical Affairs
Philip Ashman
SVP & European Managing Director
Rick Eiswirth
President & CFO
Dave Holland
SVP of Sales & Marketing
Report incorrect company information
Alimera Sciences Office Locations
Alimera Sciences has offices in Alpharetta, Lisbon, Hampshire and Berlin
Alpharetta, (HQ)
6120 Windward Pkwy
Berlin,
21 Cicerostraße
Hampshire,
Wellesley Rd
Report incorrect company information
Alimera Sciences Financials and Metrics
Alimera Sciences Revenue
Alimera Sciences's revenue was reported to be $35.91 m in FY, 2017
| USD | |
|---|---|
Revenue (Q3, 2018) | 11.1m |
Net income (Q3, 2018) | (3.4m) |
EBIT (Q3, 2018) | (2.2m) |
Market capitalization (4-Dec-2018) | 70.8m |
Closing stock price (4-Dec-2018) | 1.0 |
Cash (31-Dec-2017) | 24.1m |
EV | 81.1m |
Alimera Sciences's current market capitalization is $70.8 m.
Annual
Quarterly
Annual
Quarterly
| USD | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash | 23.1m | 41.3m | 42.0m | 61.4m | 61.3m | 48.1m | 39.3m | 23.9m | 16.6m | 33.9m | 26.7m | 26.9m | 25.6m |
Accounts Receivable | 464.0k | 1.3m | 1.0m | 1.1m | 3.4m | 7.7m | 9.4m | 9.1m | 13.3m | 13.4m | 10.8m | 13.6m | 13.5m |
Inventories | 3.0m | 1.2m | 1.4m | 1.7m | 2.1m | 1.6m | 1.7m | 1.4m | 1.2m | 913.0k | 802.0k | 1.1m | 1.7m |
Current Assets | 30.1m | 46.5m | 47.5m | 67.3m | 70.3m | 61.1m | 53.4m | 37.2m | 34.7m | 51.6m | 40.5m | 44.3m | 43.6m |
Annual
Quarterly
| USD | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | (31.5m) | (20.8m) | (19.6m) | (26.7m) | (9.8m) | (18.4m) | (19.9m) | (11.1m) | (18.0m) | (27.2m) | (6.7m) | (9.5m) | (14.8m) | (7.7m) | (11.7m) | (15.1m) |
Depreciation and Amortization | 101.0k | 36.0k | 69.0k | 151.0k | 558.0k | 1.2m | 1.9m | 689.0k | 1.4m | 2.1m | 666.0k | 1.3m | 2.0m | 649.0k | 1.3m | 1.9m |
Inventories | (2.2m) | 548.0k | 400.0k | (9.0k) | (455.0k) | (16.0k) | (88.0k) | 164.0k | 301.0k | 612.0k | (361.0k) | (719.0k) | (1.3m) | 299.0k | (651.0k) | (250.0k) |
Accounts Payable | 717.0k | 111.0k | 122.0k | 1.3m | 272.0k | (1.2m) | (1.4m) | (1.5m) | 264.0k | (2.1m) | (1.1m) | 572.0k | 98.0k | (992.0k) | 167.0k | (779.0k) |
Report incorrect company information
Alimera Sciences Online and Social Media Presence
2.01k Twitter followers
Alimera Sciences has 2.01k Twitter Followers. The number of followers has increased 0.6% month over month and increased 6% quarter over quarter
Report incorrect company information
Alimera Sciences News and Updates
September 17, 2018
Alimera Sciences Announces Nine Clinical Presentations and a Sponsored Symposium at 18th EURETINA Congress
ATLANTA, Sept. 17, 2018 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in commercialization and development of prescription ophthalmic pharmaceuticals, today announced that nine clinical presentations from real world ILUVIEN® usage in Europe and the U.S. will be ...
September 13, 2018
Alimera Sciences Announces Three Podium Presentations for ILUVIEN® to be Presented at 2018 Retina Society's Annual Meeting
ATLANTA, Sept. 13, 2018 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that two presentations will be delivered, and one poster presented, on ILUVIEN® during the ...
September 11, 2018
Global Diabetic Macular Edema Treatment Market 2018-2022 - Key Vendors are Allergan Alimera Sciences, Bausch Health, F. Hoffmann-La Roche & Regeneron Pharmaceuticals
DUBLIN, Sept 11, 2018 /PRNewswire/ -- The "Global Diabetic Macular Edema Treatment Market 2018-2022" report has been added to ResearchAndMarkets.com's offering. The Global Diabetic Macular Edema Treatment Market to grow at a CAGR of 1.45% during the period 2018-2022. Global Diabetic...
September 04, 2018
Alimera Sciences Announces Exchange of Series B Preferred Stock for Newly Issued Series C Preferred Stock
ATLANTA, Sept. 4, 2018 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that it has closed an agreement with Deerfield Management and certain of its affiliates...
July 30, 2018
Alimera Sciences Reports Second Quarter 2018 Results
ATLANTA, July 30, 2018 /PRNewswire/ -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced financial results for the three months ended June...
June 21, 2018
Alimera Sciences Appoints Mary T. Szela to its Board of Directors
ATLANTA, June 21, 2018 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced Mary T. Szela has joined its Board of Directors. Ms. Szela is currently the Chief...
Report incorrect company information
Alimera Sciences Blogs
November 09, 2018
Alimera Sciences to Present at Upcoming Investor Conferences
ATLANTA, GA / ACCESSWIRE / November 9, 2018 / Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that Dan Myers, Chief Executive Officer, will be presenting at the following investor
November 06, 2018
Alimera Sciences Reports Third Quarter 2018 Results
Monday, November 5, 2018 7:45 PM Record Net Revenue of $11.1 Million in Q3 2018; U.S. Net Revenue up 20% Record U.S. End User Demand in Q3 2018 Net Loss and Adjusted EBITDA Loss Continue to Improve ATLANTA, GA / ACCESSWIRE / November 5, 2018 / Alimera Sciences, Inc.
October 23, 2018
Alimera Sciences to Report Third Quarter 2018 Results November 5, 2018
ATLANTA, October 23, 2018 –Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that it will release its financial results for the third quarter ended September 30, 2018, after the close of the
October 22, 2018
Alimera Sciences Announces Six ILUVIEN® Posters to be Presented at 2018 American Academy of Ophthalmology
ATLANTA, October 22, 2018 –Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that six posters on ILUVIEN ® will be available during the 2018 Annual Meeting of the American Academy of
July 19, 2018
Mary T. Szela
Mary T. Szela
Matthew.Callan…
Thu, 07/19/2018 - 13:20
Member of the Audit Committee Charter Mary
T.
Szela, M.B.A., B.S.N.
Chief Executive Officer and President, Surefire Medical, Inc.
Mary T. Szela, M.B.A., has been a member of our board of directors since 2018. …
July 18, 2018
Alimera Sciences to Report Second Quarter 2018 Results July 30, 2018
ATLANTA, July 18, 2018 /PRNewswire/ -- Alimera Sciences (NASDAQ: ALIM), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that it will release its financial results for the second quarter ended June 30, 2018, after the close of the
Alimera Sciences Company Life and Culture
Report incorrect company information
Alimera Sciences Frequently Asked Questions
When was Alimera Sciences founded?
Alimera Sciences was founded in 2003.
Who are Alimera Sciences key executives?
Alimera Sciences's key executives are Ken Greene, Susan Caballa and Philip Ashman.
How many employees does Alimera Sciences have?
Alimera Sciences has 118 employees.
What is Alimera Sciences revenue?
Latest Alimera Sciences annual revenue is $35.9 m.
What is Alimera Sciences revenue per employee?
Latest Alimera Sciences revenue per employee is $304.3 k.
Who are Alimera Sciences competitors?
Competitors of Alimera Sciences include Kiniksa Pharmaceuticals, Sartorius Stedim BioOutsource and Neurosearch.
Where is Alimera Sciences headquarters?
Alimera Sciences headquarters is located at 6120 Windward Pkwy, Alpharetta.
Where are Alimera Sciences offices?
Alimera Sciences has offices in Alpharetta, Lisbon, Hampshire and Berlin.
How many offices does Alimera Sciences have?
Alimera Sciences has 4 offices.